Description
The PET/CT -18F-PSMA provides semi-quantitative metabolic imaging of abnormal prostate-specific membrane antigen (PSMA) concentrations enabling accurate assessment of prostate cancer, identifying threshold prostate-specific antigen (PSA) levels for optimal detection of recurrent prostate cancer (RC).
The level of PSMA expression has prognostic value for disease progression, both primary and metastatic.
Category: BIOMARKER
Sub - Category: Diagnostic product for “in vivo” use”
![3’-deoxi-[<sup>18</sup>F]-fluorotimidina (<sup>18</sup>F-FLT) solución.](https://tecnonuclear.com/wp-content/uploads/2025/12/ffly-300x300.jpg)
